These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26553687)

  • 1. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
    Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso.
    Tall H; Yaro S; Kpoda HB; Ouangraoua S; Trotter CL; Njanpop Lafourcade BM; Findlow H; Bai X; Martin C; Nwakamma I; Ouedraogo JB; Gessner BD; Borrow R; Mueller JE
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S540-6. PubMed ID: 26553686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher Tetanus Toxoid Immunity 2 Years After PsA-TT Introduction in Mali.
    Basta NE; Borrow R; Berthe A; Onwuchekwa U; Dembélé AT; Almond R; Frankland S; Patel S; Wood D; Nascimento M; Manigart O; Trotter CL; Greenwood B; Sow SO
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S578-85. PubMed ID: 26553691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign?
    Yaro S; Njanpop Lafourcade BM; Ouangraoua S; Ouoba A; Kpoda H; Findlow H; Tall H; Seanehia J; Martin C; Ouedraogo JB; Gessner B; Meda N; Borrow R; Trotter C; Mueller JE
    Clin Infect Dis; 2019 Jan; 68(3):435-443. PubMed ID: 30481265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays.
    Price GA; Hollander AM; Plikaytis BD; Mocca BT; Carlone G; Findlow H; Borrow R; Sow SO; Diallo A; Idoko OT; Enwere GC; Elie C; Preziosi MP; Kulkarni PS; Bash MC
    Clin Infect Dis; 2015 Nov; 61 Suppl 5():S554-62. PubMed ID: 26553688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials.
    White M; Idoko O; Sow S; Diallo A; Kampmann B; Borrow R; Trotter C
    Lancet Infect Dis; 2019 Mar; 19(3):327-336. PubMed ID: 30745277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults.
    Findlow H; Plikaytis BD; Aase A; Bash MC; Chadha H; Elie C; Laher G; Martinez J; Herstad T; Newton E; Viviani S; Papaspyridis C; Kulkarni P; Wilding M; Preziosi MP; Marchetti E; Hassan-King M; La Force FM; Carlone G; Borrow R
    Clin Vaccine Immunol; 2009 Jul; 16(7):969-77. PubMed ID: 19474264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
    van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA
    Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
    Diallo A; Sow SO; Idoko OT; Hirve S; Findlow H; Preziosi MP; Elie C; Kulkarni PS; Parulekar V; Diarra B; Cheick Haidara F; Diallo F; Tapia M; Akinsola AK; Adegbola RA; Bavdekar A; Juvekar S; Chaumont J; Martellet L; Marchetti E; LaForce MF; Plikaytis BD; Enwere GC; Tang Y; Borrow R; Carlone G; Viviani S
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S521-30. PubMed ID: 26553684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers.
    Bash MC; Lynn F; Mocca B; Borrow R; Findlow H; Hassan-King M; Preziosi MP; Idoko O; Sow S; Kulkarni P; Laforce FM
    Clin Vaccine Immunol; 2014 May; 21(5):755-61. PubMed ID: 24671551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines.
    Idoko OT; Okolo SN; Plikaytis B; Akinsola A; Viviani S; Borrow R; Carlone G; Findlow H; Elie C; Kulkarni PS; Preziosi MP; Ota M; Kampmann B
    Vaccine; 2014 Jul; 32(33):4220-7. PubMed ID: 24863486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.
    Holme D; Findlow H; Sow SO; Idoko OT; Preziosi MP; Carlone G; Plikaytis BD; Borrow R
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S563-9. PubMed ID: 26553689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.
    Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K
    Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
    Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.
    Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J
    Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.
    Trotter CL; Borrow R; Findlow J; Holland A; Frankland S; Andrews NJ; Miller E
    Clin Vaccine Immunol; 2008 Nov; 15(11):1694-8. PubMed ID: 18827191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents.
    Quiambao BP; Bavdekar A; Dubey AP; Jain H; Kolhe D; Bianco V; Miller JM; Van der Wielen M
    Hum Vaccin Immunother; 2017 Mar; 13(3):636-644. PubMed ID: 28152332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years.
    Vesikari T; Forstén A; Boutriau D; Bianco V; Van der Wielen M; Miller JM
    Hum Vaccin Immunother; 2012 Dec; 8(12):1882-91. PubMed ID: 23032168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
    Tejedor JC; Merino JM; Moro M; Navarro ML; Espín J; Omeñaca F; García-Sicilia J; Moreno-Pérez D; Ruiz-Contreras J; Centeno F; Barrio F; Cabanillas L; Muro M; Esporrin C; De Torres MJ; Caubet M; Boutriau D; Miller JM; Mesaros N
    Pediatr Infect Dis J; 2012 Oct; 31(10):1074-7. PubMed ID: 22828645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.